Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma supplement trial fizzles: MEMOPTIC study halted early

NCT ID NCT04499157

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily tablet called MEMOPTIC (containing citicoline, magnesium, and Ginkgo biloba) could help preserve vision in people with open-angle glaucoma when added to their usual eye-pressure-lowering treatments. The trial planned to follow 15 patients for two years, but it was terminated early. Because of the small size and early stop, no firm conclusions can be drawn about whether MEMOPTIC helps protect vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MEMOPTIC (a tablet combining citicoline, magnesium, and Ginkgo biloba)
What this could lead to
If it worked, MEMOPTIC might help preserve vision in glaucoma patients when added to standard pressure-lowering treatments.
What could go wrong
The trial was terminated early and included only 15 people, so results are very limited. It is unclear if the supplement provides any real benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Sep 2020

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of GCAO defined by OCT RNFL alterations and visual fields defects * age between 20 and 80 years old * Well controled intra-ocular pressure under treatment (PIO\<21mmHg or decreased by 20% compared to initial the PIO) Exclusion Criteria: * retinal or macular disease * diagnosis of cataract or surgery of cataract during the follow-up * allergy to citicolin * ocular hypertonia due to a secondary cause (like corticosteroids) * history of anterior, intermediate or posterior uveitis * general treatment affecting PIO (beta blockers, corticosteroids) * pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma Visual field

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.